Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

66
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
66
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

54
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
54
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

93
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
93
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

118
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
118
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

60
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
60
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

31
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
31

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis.

Arthritis research & therapy·2019
Same author

Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2017
Same author

CT imaging of solid renal masses: pitfalls and solutions.

Clinical radiology·2017
Same author

Analysis of distribution and severity of inflammation in patients with osteoarthitis compared to rheumatoid arthritis by ICG-enhanced fluorescence optical imaging and musculoskeletal ultrasound: a pilot study.

Annals of the rheumatic diseases·2015
Same author

Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2014
Same author

[Imaging modalities in psoriatic arthritis].

Zeitschrift fur Rheumatologie·2013
Same journal

Rheuma plus·2023
Same journal

[Rheumatology-Quo Vadis? Health System-Quo Vadis?]

Rheuma plus·2023
Same journal

Rheuma plus·2023
Same journal

Rheuma plus·2023
Same journal

[Paediatric Rheumatology News: Return to Normality After the Pandemic?]

Rheuma plus·2023
Same journal

Rheuma plus·2023
See all related articles

Related Experiment Video

Updated: Oct 14, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

409

[COVID-19 in Routine Rheumatologic Care].

S G Werner1, H-E Langer1, R Chatelain2,3

  • 1RHIO (Rheumatologie, Immunologie und Osteologie) Düsseldorf und RHIO Forschungsinstitut Düsseldorf, Reichsstr. 59, 40217 Düsseldorf, Deutschland.

Rheuma Plus
|November 8, 2021
PubMed
Summary
This summary is machine-generated.

Patients with inflammatory rheumatic diseases on DMARD therapy may not be at high risk for severe COVID-19. Further research is needed on vaccine efficacy and protective factors against SARS-CoV-2 infection.

Keywords:
DMARD therapyInflammatory rheumatic diseasePCR testRisk populationSARS-CoV‑2

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

472
Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
09:18

Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue

Published on: February 24, 2023

8.8K

Related Experiment Videos

Last Updated: Oct 14, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

409
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

472
Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
09:18

Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue

Published on: February 24, 2023

8.8K

Area of Science:

  • Rheumatology
  • Infectious Diseases
  • Immunology

Context:

  • The COVID-19 pandemic caused by SARS-CoV-2 has had significant global health and societal impacts.
  • Patients with inflammatory rheumatic diseases on immunosuppressive/immunomodulatory therapy (DMARD) were initially presumed at high risk for severe COVID-19.
  • Diagnostic challenges exist, as PCR testing alone may not always confirm COVID-19, suggesting a role for antibody testing.

Purpose:

  • To evaluate the actual risk of SARS-CoV-2 infection and severe COVID-19 in patients with inflammatory rheumatic diseases on DMARD therapy.
  • To explore the utility of antibody testing for COVID-19 diagnosis in conjunction with PCR.
  • To identify factors potentially influencing COVID-19 outcomes in this patient population.

Summary:

  • Contrary to initial assumptions, patients with inflammatory rheumatic diseases undergoing DMARD therapy do not appear to be at significantly higher risk for severe SARS-CoV-2 infection.
  • The role of antibody testing as a complementary diagnostic tool for COVID-19, especially in cases with negative PCR, is highlighted.
  • The protective mechanisms, whether behavioral (hygiene, restrictions) or therapeutic (DMARDs), remain unclear and require further investigation.

Impact:

  • Findings suggest a potential re-evaluation of risk stratification for rheumatic disease patients during pandemics.
  • Highlights the need for continued research into COVID-19 pathogenesis, diagnosis, and management in immunocompromised populations.
  • Underscores the importance of addressing vaccine tolerability and efficacy in patients with inflammatory rheumatic diseases.